Page last updated: 2024-12-09

4-amino-5-hydrazino-1,2,4-triazole-3-thiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-amino-5-hydrazino-1,2,4-triazole-3-thiol: for detection of aldehydes as a spray reagent; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2723946
CHEMBL ID1531579
SCHEMBL ID37997
MeSH IDM0049150

Synonyms (72)

Synonym
4-amino-3-hydrazino-1,2,4-triazol-5-thiol
4-amino-5-hydrazinyl-4h-[1,2,4]triazole-3-thiol
nsc-49106
nsc49106
4-amino-5-hydrazino-2,4-dihydro-3h-1,2,4-triazole-3-thione
4-amino-3-hydrazino-1h-1,2,4-triazole-5-thione
nsc682569
.delta.2-1,4-triazoline-5-thione, 4-amino-3-hydrazino-
1,4-triazolidin-3-one, 4-amino-5-thioxo-, 3-hydrazone
nsc-12519
purpald
nsc12519
1750-12-5
4-amino-5-hydrazino-4h-[1,2,4]triazole-3-thiol
smr000438264
MLS000762979
nsc-682569
purpald(r), >=99%
A0956
AKOS000293129
4-amino-3-hydrazino-5-mercapto-1,2,4-triazole
4-amino-3-hydrazinyl-1h-1,2,4-triazole-5-thione
A811703
4-azanyl-3-diazanyl-1h-1,2,4-triazole-5-thione
NCGC00246498-01
AKOS015918150
4-amino-5-hydrazinyl-4h-1,2,4-triazole-3-thiol
STK744362
delta2-1,2,4-triazoline-5-thione, 4-amino-3-hydrazino-
nsc 49106
nsc 12519
ai3-62547
4-amino-5-hydrazino-3-mercapto-1,2,4-triazole
3h-1,2,4-triazole-3-thione, 4-amino-5-hydrazinyl-2,4-dihydro-
1,2,4-triazolidin-3-one, 4-amino-5-thioxo-, 3-hydrazone
1,2,4-triazolidin-3-one, 4-amino-5-thioxo-, hydrazone
l49pbf7wzf ,
4-amino-5-thioxo-1,2,4-triazolidin-3-one hydrazone
einecs 217-135-8
unii-l49pbf7wzf
4-amino-5-hydrazino-1,2,4-triazole-3-thiol
FT-0617495
AM84614
BBL027417
SCHEMBL37997
DTXSID1061944
3-hydrazino-4-amino-5-mercapto-1,2,4-triazole
.delta.2-1,2,4-triazoline-5-thione, 4-amino-3-hydrazino-
4-amino-5-hydrazino-2,4-dihydro-3h-1,2,4-triazole-3-thione #
4-amino-5-hydrazono-(1,2,4)-triazolidine-3-thione
3-hydrazino-4-amino-1,2,4-triazin-5-thione
1,2,4-1h-triazole-3-one-5(4h)-thione, 4-amino-, hydrazone
purpald(r)
W-107848
CHEMBL1531579
4-amino-3-hydradzino-5-mercapto-1,2,4-triazole
AC-24651
mfcd00003098
4-amino-5-hydrazino-4h-1,2,4-triazole-3-thiol
3h-[1,2,4]triazole-3-thione,4-amino-5-hydrazinyl-2,4-dihydro-
4-amino-5-hydrazinyl-2,4-dihydro-3h-1,2,4-triazole-3-thione
Q25323975
FS-4234
nsc-812159
nsc812159
nsc 12519; nsc 49106; nsc 682569; purpald
D93179
4-amino-3-hydrazino-4h-[1,2,4]triazole-5-thiol
STL577166
ahmt (hydrazone)
4-amino-5-hydrazinylidene-1,2,4-triazolidine-3-thione
EN300-70549

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The removal efficacy for activated carbon was higher for fine particles than for coarse particles, and a dose-response relationship was established."( [Development of the new desiccator system for measuring the removal effect of the formaldehyde as an indoor air pollutant by the adsorbent].
Hoshino, T; Kumagai, T; Mihara, Y; Ogawa, N; Tsutsumi, H; Yokota, K, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency7.07950.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency9.05870.140911.194039.8107AID2451; AID2787
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency0.56230.177814.390939.8107AID2147
phosphopantetheinyl transferaseBacillus subtilisPotency2.81840.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency0.11580.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency13.97110.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency5.62340.180013.557439.8107AID1468
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency39.81070.707912.194339.8107AID720542
regulator of G-protein signaling 4Homo sapiens (human)Potency70.79460.531815.435837.6858AID504845
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency35.48130.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency25.11890.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency8.91250.036619.637650.1187AID2100
fructose-bisphosphate aldolase AOryctolagus cuniculus (rabbit)Potency18.33750.891316.576239.8107AID2794
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.08200.00419.984825.9290AID504444
glyceraldehyde-3-phosphate dehydrogenase isoform 1Homo sapiens (human)Potency18.33751.122011.187739.8107AID2795
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency15.84890.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546; AID2551
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency3.16230.00419.962528.1838AID2675
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency3.16230.025911.239831.6228AID602313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
recombinase AMycobacterium tuberculosis H37RvEC50 (µMol)233.20000.018023.2882287.6000AID434968; AID435010
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
replicative DNA helicaseMycobacterium tuberculosis H37RvAC50206.16000.057030.7482325.3000AID449749; AID449750
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (18.18)18.7374
1990's4 (18.18)18.2507
2000's6 (27.27)29.6817
2010's5 (22.73)24.3611
2020's3 (13.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.63 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]